Showing results (101-110 of 145) with videos related to
Sort By:
Pageof 15
The Lancet. Oncology|July 10, 2015
Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trialJean-Charles Soria, Enriqueta Felip, Manuel Cobo, et al.Lung Cancer (Amsterdam, Netherlands)|April 25, 2013
Randomized phase II trial of non-platinum induction or consolidation chemotherapy plus concomitant chemoradiation in stage III NSCLC patients: mature results of the Spanish Lung Cancer Group 0008 studyPilar Garrido, Rafael Rosell, Antonio Arellano, et al.Lung Cancer (Amsterdam, Netherlands)|August 14, 2010
First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patientsFernanda Salazar, Miguel Angel Molina, Maria Sanchez-Ronco, et al.Cancers|August 29, 2024
Peripheral Blood TCRβ Repertoire, IL15, IL2 and Soluble Ligands for NKG2D Activating Receptor Predict Efficacy of Immune Checkpoint Inhibitors in Lung CancerAndrea Sesma, Julian Pardo, Dolores Isla, et al.Journal of Translational Medicine|December 21, 2010
Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancerSara Simonetti, Miguel Angel Molina, Cristina Queralt, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 3, 2007
Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancerManuel Cobo, Dolores Isla, Bartomeu Massuti, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 9, 2005
Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancerRicardo Hitt, Antonio López-Pousa, Javier Martínez-Trufero, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2007
Long-term survival associated with complete resection after induction chemotherapy in stage IIIA (N2) and IIIB (T4N0-1) non small-cell lung cancer patients: the Spanish Lung Cancer Group Trial 9901Pilar Garrido, José Luis González-Larriba, Amelia Insa, et al.European Journal of Cancer (Oxford, England : 1990)|February 7, 2020
CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populationsEnriqueta Felip, Andrea Ardizzoni, Tudor Ciuleanu, et al.The Lancet. Oncology|September 15, 2022
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trialMary O'Brien, Luis Paz-Ares, Sandrine Marreaud, et al.Pageof 15